ESMO 2024: Regeneron’s melanoma combo therapy benefit continues beyond two years
Regeneron Pharmaceuticals’ investigational melanoma combination therapy shows continued response after two years in a Phase I trial. The company presented…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is a healthcare reporter for the Clinical Trials Arena. Coming from a journalistic background Abigail holds a BA (Hons) in Journalism from the University of Central Lancashire. Based in Manchester, Abigail has previously worked in local news and has interests in research into the treatment and prevention of cancer, heart disease and dementia.
-
-
ESMO 2024: Moderna’s mRNA solid tumour vaccine shows early promise
Moderna’s mRNA cancer vaccine for solid tumours shows early signs of promise in interim data from a Phase I study.…
-
How the Covid-19 pandemic will help researchers with the mpox emergency
In 2020, researchers from across the globe united under pressure to find a vaccine for Covid-19. Now, four years later,…
-
Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints
Viridian Therapeutics’s veligrotug has met all primary and secondary endpoints in a Phase III trial in active thyroid eye disease…
-
J&J’s Rybrevant combo for NSCLC remains better than SOC after three years
The Rybrevant combination therapy by Johnson & Johnson (J&J) continues to be effective after three years in a study of…
-
Moderna mpox mRNA vaccine shows early promise in monkey study
Moderna has announced its mRNA vaccine in development for mpox is more effective than Bavarian Nordics Jynneos in prevention of…
-
Roche’s BTK inhibitor shines in multiple sclerosis trial
Roche has presented more data from a Phase II study of its Bruton’s tyrosine kinase (BTK) inhibitor after long-term data…
-
Arrowhead to file NDA after pivotal rare disease trial meets all endpoints
Arrowhead Pharmaceuticals is looking to file a new drug application (NDA) with the US Food and Drug Administration (FDA) after…
-
Nykode scraps Phase II trial of cancer vaccine in pipeline reshuffle
Nykode Therapeutics is halting a Phase II trial of its cancer vaccine in patients with second-line cervical cancer as it…
-
Build or buy? Key considerations for in-house manufacturing
For small and medium-sized biotech’s, for many years the common practice has been to outsource to both contract research organisations…